HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (13) Citing Articles via Google Scholar Google Scholar Articles by Lobato, M. N. Search for Related Content PubMed PubMed Citation Articles by Lobato, M. N.

Adverse Events and Treatment Completion for Latent Tuberculosis in Jail Inmates and Homeless Persons^*

Mark N. Lobato, MD; Randall R. Reves, MD, MSc; Robert M. Jasmer, MD; John C. Grabau, PhD; Naomi N. Bock, MD; Nong Shang, PhD; for the 2RZ Study Group

^* From the Division of Tuberculosis Elimination (Drs. Lobato, Bock, and Shang), National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention; the Denver Public Health Department (Dr. Reves), Denver, CO; the University of California-San Francisco (Dr. Jasmer), San Francisco, CA; and the Bureau of Tuberculosis Control (Dr. Grabau), New York State Department of Health, New York, NY. For a list of 2EZ Study Group members see the ^Appendix.

Correspondence to: Mark N. Lobato, MD, CDC, 1600 Clifton Rd, Mailstop E-10, Atlanta, GA 30333; e-mail: mnl0{at}cdc.gov

Background: Recently, a short-course treatment using 60 daily doses of rifampin and pyrazinamide was recommended for latent tuberculosis (TB) infection (LTBI).

Study objectives: To determine the acceptability, tolerability, and completion of treatment.

Design: Observational cohort study.

Setting: Five county jails and TB outreach clinics for homeless populations in three cities.

Patients: Study staff enrolled 1,211 patients (844 inmates and 367 homeless persons).

Interventions: Sites used 60 daily doses of rifampin and pyrazinamide, an approved treatment regimen for LTBI.

Measurements: Types and frequency of drug-related adverse events and outcomes of treatment.

Results: Prior to treatment, 25 of 1,178 patients (2.1%) had a serum aminotransferase measurement at least 2.5 times the upper limit of normal. Patients who reported excess alcohol use in the past 12 months were more likely than other patients to have an elevated pretreatment serum aminotransferase level (odds ratio, 2.1; 95% confidence interval, 1.1 to 6.1; p = 0.03). Treatment was stopped in 66 of 162 patients (13.4%) who had a drug-related adverse event. Among 715 patients who had serum aminotransferase measured during treatment, 43 patients (6.0%) had an elevation > 5 times the upper limits of normal, including one patient who died of liver failure attributed to treatment. In multivariate analyses, increasing age, an abnormal baseline aspartate aminotransferase level, and unemployment within the past 24 months were independent risk factors for hepatotoxicity. Completion rates were similar in jail inmates (47.5%) and homeless persons (43.6%).

Conclusions: This study detected the first treatment-associated fatality with the rifampin and pyrazinamide regimen, prompting surveillance that detected unacceptable levels of hepatotoxicity and retraction of recommendations for its routine use. Completion rates for LTBI treatment using a short-course regimen exceeds historical rates using isoniazid. Efforts to identify an effective short-course treatment for LTBI should be given a high priority.

Key Words: antitubercular agents • homeless persons • mycobacterial infection • prisons • tuberculosis

This article has been cited by other articles:

				H. M. Blumberg, M. K. Leonard Jr, and R. M. Jasmer Update on the Treatment of Tuberculosis and Latent Tuberculosis Infection JAMA, June 8, 2005; 293(22): 2776 - 2784. [Abstract] [Full Text] [PDF]